It is made available under a	CC-BY	4.0 International	license .
------------------------------	-------	-------------------	-----------

1	Multiomic Mendelian randomization-based insights
2	into the role of neutrophil extracellular trap-related
3	genes in sepsis
4	
5	Yanbo Liu ^{1,¶,} *,Yuhui Li ^{2,¶} ,Jinmin Chen¹, Yongxia Cai¹, Lukai Lv³
6	¹ Department of Emergency, Sir Run Run Shaw Hospital, Zhejiang University School of
7	Medicine, Hangzhou, Zhejiang Province, China.
8	² Department of Ultrasonography Lab, Women's Hospital, Zhejiang University School of
9	Medicine, Hangzhou, Zhejiang Province, China.
10	³ Department of Emergency, Wuyi County People's Hospital, Jinhua, Zhejiang Province,
11	China.
12	
13	[¶] Equal contribution
14	*Corresponding author:
15	Yanbo Liu
16	Email: 1282686740@qq.com
17	
18	Short title: MR analysis of NET-related genes in sepsis
19	
20	
21	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 Abstract

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to 23 24 infection. Neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of sepsis, yet the precise role of NET-related genes (NRGs) remains unclear. This study 25 employed a multiomic Mendelian randomization (MR) approach, leveraging genetic variants 26 as instrumental variables to investigate the relationships between NRGs and sepsis risk. We 27 28 systematically identified 69 NRGs based on literature and database reviews. Utilizing the IEU OpenGWAS Project database, we extracted genetic data for sepsis cases and controls. 29 30 Expression quantitative trait loci, methylation quantitative trait loci (mQTLs), and protein 31 quantitative trait loci (pQTLs) associated with NRGs were obtained from the eQTLGen Consortium, mOTL meta-analysis, and deCODE Genetics datasets, respectively. We 32 33 employed the inverse variance-weighted method, supplemented by MR-Egger regression, weighted median, and Bayesian colocalization analysis, and identified four genes (CXCR1, 34 35 CXCR2, ENTPD4, and MAPK3) significantly associated with sepsis risk. Three CpG sites 36 associated with these genes were identified through mQTL-based MR analysis. Additionally, 37 ten proteins showed significant associations with sepsis risk in pQTL-based MR analysis. Summary-data-based MR and colocalization analyses confirmed the causal relationship 38 39 between CXCR2 and sepsis, which remained unaffected by pleiotropy. The DNA methylation 40 level at cg06547715, located in the CXCR2 enhancer region, was inversely correlated with CXCR2 expression and sepsis risk. These findings suggest that NRGs, particularly CXCR2, 41 42 play a crucial role in sepsis susceptibility and that the DNA methylation status of CXCR2 may modulate gene expression, influencing sepsis risk. This study provides novel insights into the 43

49	Keywords: Sepsis, Neutrophil Extracellular Traps, Mendelian Randomization, Multiomics,
48	
47	pathogenesis and pave the way for future research into precision medicine for sepsis.
46	management. These findings contribute to the theoretical understanding of sepsis
45	Targeting CXCR2 and its regulatory mechanisms may offer a new avenue for sepsis
44	molecular epidemiology of sepsis and highlights the potential of NRGs as therapeutic targets.

50 *CXCR2*, DNA Methylation

51 Introduction

Sepsis, an abnormal response to infection, is a leading cause of death among critically ill 52 patients worldwide[1, 2]. Marked by systemic inflammation, it can quickly lead to organ 53 failure and death in the absence of prompt treatment[3, 4]. The pathophysiology of sepsis is 54 55 complex, involving an intricate interplay among the host immune system, coagulation cascade, and endothelium [5, 6]. Despite advances in critical care and antibiotic therapy, 56 sepsis management continues to pose a significant challenge, highlighting the need for 57 attaining a deeper understanding of the mechanisms underlying this condition and for the 58 59 development of novel therapeutic strategies[7-9].

Recent studies have highlighted the role of neutrophil extracellular traps (NETs) in the 60 pathogenesis of sepsis, particularly in the context of COVID-19 infections, wherein NETs 61 62 have been implicated in the hyperinflammatory response and microthrombi formation[10, 11]. Neutrophils, the most abundant leukocytes in the human body, play a pivotal role in the 63 innate immune response against infections[12, 13]. Among their various defense mechanisms, 64 65 the formation of NETs has emerged as a critical process in pathogen clearance[14]. NETs are web-like structures composed of DNA, histones, and antimicrobial proteins, which are 66 released by neutrophils through a process termed NETosis[15, 16]. While NETs are effective 67 in trapping and neutralizing a broad spectrum of microbes, excessive NET formation has been 68 69 implicated in the pathogenesis of various inflammatory and thrombotic conditions, including sepsis[17, 18]. The recognition of NETs in the context of sepsis has led to a paradigm shift in 70 71 understanding the role of neutrophils in disease pathogenesis. NETs have been shown to 72 contribute to the formation of microthrombi, exacerbating tissue injury and organ dysfunction

during sepsis[19, 20]. Furthermore, NETs can serve as a source of proinflammatory
mediators, potentially driving the systemic inflammation observed in sepsis[21, 22].

75 The involvement of NETs in sepsis is increasingly being recognized, but the mechanisms governing their formation and their impact on disease severity remain poorly understood[23]. 76 77 Given the potential impact of NETs on sepsis outcomes, elucidating the genetic and molecular factors that regulate NETosis is an urgent need. Identifying key regulators of NET 78 79 formation may reveal novel therapeutic targets for mitigating the detrimental effects of excessive NET production in sepsis. In this study, we employed two-sample Mendelian 80 81 randomization (MR), a powerful epidemiological tool that leverages genetic variants as instrumental variables (IVs)[24]. Through the analysis of large-scale genome-wide 82 association studies (GWASs) and quantitative trait loci (OTL), we investigated the causal 83 84 relationship between NETosis-related genes (NRGs) and sepsis risk.

85

86 Materials and methods

87 Data acquisition

88 Identification of NRGs

We systematically identified and curated a comprehensive list of 69 NRGs based on a thorough review of the existing literature and databases[14, 25], focusing on the role of NETs in immunity and various diseases. The selection criteria for these genes included their involvement in the formation, regulation, and biological impact of NETs, encompassing ligands and receptors that stimulate NETs, downstream signaling pathways, and molecules known to be components of the NET framework (**S1 Table**).

95 Data sources of methylation, expression, and protein QTLs

We accessed publicly available genomic data relevant to sepsis using the "IEU 96 97 OpenGWAS Project" database. This database, known for its extensive collection of GWAS data, provided a robust platform for our investigation. Specifically, we extracted data from the 98 hospital episode statistics, which included two sepsis datasets—a primary dataset 99 (ieu-b-4980) consisting of 11,643 sepsis cases and 474,841 control participants, and a 100 validation dataset (ieu-b-5088) comprising 11,568 sepsis cases and 451,301 control subjects 101 102 (S2 Table). Both datasets included individuals of European ancestry, ensuring genetic 103 homogeneity was maintained for the MR analyses. To screen for expression quantitative trait locus (eQTL) IVs of the NRGs, genetic variants robustly associated with gene expression 104 within a 1000 kb range on either side of the coding sequence (cis) were extracted from the 105 106 eQTL summary statistics obtained from the eQTLGen Consortium (https://www.eqtlgen.org/cis-eqtls.html). The eQTLGen Consortium includes information on 107 10,317 single nucleotide polymorphisms (SNPs) associated with traits from 31,684 108 109 individuals. Using the methylation quantitative trait locus (mQTL) data from a meta-analysis 110 summary statistics from cohorts 1980) available of two (n at = (https://yanglab.westlake.edu.cn/data/SMR/LBC BSGS meta lite.tar.gz), cis-mQTL IVs 111 robustly associated with NRG methylation were extracted. From the deCODE Genetics 112 dataset of 4907 proteins (https://www.decode.com/summarydata/), cis-protein quantitative 113 trait locus (pQTL) IVs associated with the expression of proteins related to NRGs were 114 115 selected; all SNPs included in the initial analysis met the criterion of $P < 5 \times 10^{-8}$.

116 **MR analysis**

117 Assumptions and approach

We used two-sample MR to examine the causal relationships between the QTLs of 69 118 NRGs and sepsis development. The two-sample MR technique utilizes genetic variants as IVs 119 to estimate the causal effects of modifiable risk factors by leveraging the random assortment 120 of alleles at conception. The application of MR in this study was based on three key 121 assumptions—(1) IVs are strongly associated with the exposure of interest; (2) IVs are 122 123 independent of confounders that could influence the outcome; (3) IVs affect the outcome solely through exposure. Deviations from these assumptions, particularly through pleiotropy, 124 125 where IVs affect the outcome through multiple biological pathways, can bias MR estimates.

126 IV selection

The selection of IVs for each NRG was based on established criteria. eQTLs, mQTLs, 127 128 and pQTLs associated with NRGs were considered as potential IVs. The criteria for IV selection included the following: (1) a genome-wide significant association between the SNP 129 and the gene $(P < 5 \times 10^{-8})$; (2) minimal linkage disequilibrium among SNPs (r² < 0.1) with a 130 131 threshold distance of 10,000 kb to ensure independence; (3) exclusion of SNPs with palindromic sequences to harmonize exposure and outcome datasets, followed by 132 MR-PRESSO testing to exclude outlier SNPs; (4) an F-statistic ≥ 10 [F-statistic = 133 (beta/se)²][26] to ensure sufficient statistical power for the IVs in the analysis. 134

135

Two-sample MR analysis and assessment of heterogeneity and pleiotropy

136 The primary two-sample MR analysis was conducted using the inverse 137 variance-weighted (IVW) method. Before IVW analysis, the datasets were assessed for 138 heterogeneity using Cochran's Q test with a significance threshold of P < 0.05. A

random-effects IVW model was used in the presence of significant heterogeneity, while a 139 fixed-effects IVW model was applied when no heterogeneity was detected. Complementary 140 141 MR methods were employed to strengthen the findings, including MR-Egger regression, weighted median, weighted model, and simple model. The *P*-values were adjusted to control 142 143 the false discovery rate (FDR) at $\alpha = 0.05$ using the Benjamini-Hochberg method. The estimated causal effects were quantified using the odds ratio (OR) and the 95% confidence 144 interval (CI). The MR-Egger regression intercept test was used to assess potential pleiotropy, 145 with a non-significant P > 0.05 indicating the absence of horizontal pleiotropy. Cochran's Q 146 147 statistic from both the MR-Egger and IVW methods was used to detect heterogeneity among various causal effects, with a Cochran's Q test P < 0.05 indicating heterogeneity[26, 27]. We 148 also employed the Steiger filtering method to verify the directional associations among 149 150 eQTLs, mQTLs, and sepsis.

151 Summary-data-based MR (SMR)

152 SMR analysis and heterogeneity in the dependent instrument (HEIDI) testing

153 SMR was employed to ascertain the causal inferences of NRG methylation, expression, and protein abundance with the risk of sepsis, based on the top associated cis-QTLs. SMR can 154 reach a much higher statistical power than conventional MR analysis when exposure and 155 outcome are available from two independent samples with large sample sizes. The top 156 associated cis-QTLs were selected by considering a window centered around the 157 corresponding gene (± 1000 kb) and passing a *P*-value threshold of 5.0×10^{-8} . The SNPs with 158 159 allele frequency differences larger than the specified threshold (set as 0.2 in the present study) between any pairwise datasets, including the linkage disequilibrium reference sample, the 160

QTL summary data, and the outcome summary data, were excluded. The HEIDI test was applied to distinguish pleiotropy from linkage, where P-HEIDI values <0.01 were considered to be likely due to pleiotropy and thus discarded from the analysis. SMR and HEIDI tests were implemented using the SMR software (version 1.3.1).

165 Colocalization analysis

To confirm the results, we used the coloc R package (version 5.2.3, available at 166 https://chr1swallace.github.io/coloc/)[28] for Bayesian collocation analysis to estimate the 167 posterior probabilities of shared variants. The collocation analysis relies on four 168 169 hypotheses—(1) Phenotype 1 (GWAS) and Phenotype 2 (e.g., eQTL) show no significant SNP associations in a specific genomic region (H0); (2) Phenotype 1 (GWAS) or Phenotype 2 170 (e.g., eOTL) shows a significant association with SNPs in a specific genomic region (H1/H2); 171 172 (3) Phenotype 1 (GWAS) and Phenotype 2 (e.g., eQTL) are significantly associated with SNPs in a specific genomic region, but driven by different causal variants (H3); (4) 173 Phenotype 1 (GWAS) and Phenotype 2 (e.g., eQTL) are significantly associated with SNPs in 174 175 a specific genomic region and driven by the same causal variant (H4). We extracted all SNPs within 100 kb upstream and downstream of the lead SNP in the GWAS for collocation 176 analysis and calculated the posterior probability H4 (PPH4). In academic contexts, a PPH4 177 value exceeding 0.75 is conventionally employed as the threshold to indicate evidence of 178 collocation between GWAS and QTL associations. 179

180 Ethical Considerations

The data sources utilized in this study, including the IEU OpenGWAS Project, eQTLgen,
the mQTL summary data of McRae et al., and the deCODE Genetics dataset, are all publicly

- accessible and do not contain any personal identifiers or sensitive personal information that
- 184 would require consent. The study followed the Declaration of Helsinki principles and human
- 185 subject research guidelines.

186 **Results**

187 Analytical process overview

- 188 In this study, two-sample MR analysis of IVs was performed separately for sepsis at the
- 189 levels of gene expression, methylation, and protein abundance to identify candidate genes
- 190 associated with sepsis. These genes were validated using SMR analysis, and significant
- eQTLs and mQTLs were advanced to an integrated analysis followed by validation in an
- independent cohort. This rigorous process culminated in the identification of CXCR2 as a
- 193 notably associated gene (**Fig 1**).

194

195 Fig 1. Overview of the study design.

196

197 eQTL-based MR analysis

By intersecting our NRGs with key cis-eQTLs from the eQTLGen consortium, we identified 62 genes that met our criteria. Applying the established criteria for selecting IVs, we identified 438 cis-eQTLs associated with these 62 NRGs as the final IVs within our exposure data. A two-sample MR analysis of patients with sepsis was performed. Using the IVW method as our primary analytical approach, we identified four genes significantly associated with sepsis risk (FDR<0.05) (**S3 Table, Fig 2**). These genes include *CXCR1* (OR: 1.11, 95% CI: 1.04–1.17; FDR = 2.21×10^{-2}), *CXCR2* (OR: 1.14, 95% CI: 1.07–1.21; FDR =

205 2.68 × 10⁻³), *ENTPD4* (OR: 1.16, 95% CI: 1.09–1.24; FDR = 2.49×10^{-4}), and *MAPK3* (OR:

206 0.96, 95% CI: 0.93–0.99; FDR = 4.59×10^{-2}). The primary analysis demonstrated the absence

of heterogeneity (P > 0.05, S4 Table) and pleiotropy (P > 0.05, S5 Table). Additionally,

208 Steiger filtering corroborated the directional relationship between outcomes and exposures

209 (S6 Table).

210

Fig 2. Mendelian randomization results for the association between the expression of neutrophil extracellular trap-related genes and sepsis risk.

213

214 mQTL-based MR analysis

To further explore the epigenetic mechanisms influencing susceptibility to sepsis, we 215 216 analyzed mQTLs associated with NRGs. Following stringent criteria for selecting IVs, we identified 780 cis-mQTLs across 55 NRGs that qualified as the final IVs within our exposure 217 dataset. We then performed two-sample MR analysis of patients with sepsis. Using the IVW 218 219 method as our primary analytical approach, we identified three CpG sites significantly associated with the sepsis risk (FDR<0.05) (S7 Table, Fig 3). These sites include 220 221 cg06547715 (OR: 0.92, 95% CI: 0.88–0.97; FDR = 2.06×10^{-2}), cg14150666 (OR: 0.95, 95% CI: 0.93–0.97; FDR = 3.46×10^{-3}), and cg24126361 (OR: 0.97, 95% CI: 0.95–0.99; FDR = 222 2.06×10^{-2}), associated with the genes CXCR2 and CXCR1, respectively. The primary 223 analysis did not indicate any evidence of heterogeneity (P > 0.05, **S8 Table**) or pleiotropy 224 225 (P > 0.05, S9 Table).

Fig 3. Mendelian randomization results for the association between neutrophil

- 228 extracellular trap-related gene methylation and sepsis risk.
- 229
- 230 pQTL-based MR analysis

231	By screening cis-pQTL data associated with NRGs, we identified 2304 SNPs across 36
232	NRGs in the exposure data as the final IVs based on the selection criteria (FDR < 0.05). Ten
233	proteins were independently associated with sepsis risk. SIGLEC14 (OR: 1.02, 95% CI:
234	1.01–1.04; FDR = 8.05 × 10 ⁻³) and <i>SIGLEC5</i> (OR: 1.02, 95% CI: 1.01–1.04; FDR = 1.13 × $1.01-1.04$; FDR = 1.13×10^{-3})
235	10 ⁻²) were positively associated with sepsis risk. Conversely, AKT2 (OR: 0.94, 95% CI:
236	0.90–0.97; FDR = 4.41 × 10 ⁻³), <i>CEACAM3</i> (OR: 0.75, 95% CI: 0.66–0.85; FDR = 7.57 ×
237	10 ⁻⁵), <i>CTSG</i> (OR: 0.80, 95% CI: 0.69–0.92; FDR = 8.77 × 10 ⁻³), <i>F3</i> (OR: 0.70, 95% CI:
238	0.61–0.82; FDR = 7.57×10^{-5}), FCAR (OR: 0.72, 95% CI: 0.56–0.91; FDR = 2.07×10^{-2}),
239	<i>HMGB1</i> (OR: 0.83, 95% CI: 0.76–0.90; FDR = 7.57 × 10 ⁻⁵), <i>IL17A</i> (OR: 0.63, 95% CI:
240	0.44–0.90; FDR = 3.55×10^{-2}), and <i>ITGB2</i> (OR: 0.77, 95% CI: 0.69–0.88; FDR = 3.19×10^{-2})
241	10^{-4}), were inversely associated with sepsis risk (S10 Table, Fig 4). In the primary analysis,
242	no heterogeneity ($P > 0.05$, S11 Table) or horizontal pleiotropy ($P > 0.05$, S12 Table) was
243	observed.

244

Fig 4. Mendelian randomization results for the association between neutrophil
extracellular trap-related proteins and sepsis risk.

247

248 SMR and colocalization analyses

249	Further SMR analysis was conducted to verify the causal relationships between mQTLs
250	and sepsis, eQTLs and sepsis, as well as pQTLs and sepsis. The protein data were not
251	significant after SMR analysis, and the CXCR2 gene was identified through mQTL and eQTL
252	SMR analyses. The results indicated that CXCR2 was consistent with the direction of the
253	effect observed in the MR analysis and passed the HEIDI ($P > 0.01$) and SMR tests ($P <$
254	0.05), suggesting a causal relationship unconfounded by pleiotropy. The SMR plots and effect
255	estimates are presented in the S13 Table and Fig 5A, B. Other genes did not demonstrate
256	significant associations in these analyses. Upon further exploring the causal relationships
257	between these genes and sepsis, colocalization analysis revealed the details of SNPs (Fig 5B)
258	and showed that <i>CXCR2</i> (OR: 1.16, 95% CI: 1.05–1.29; PPH4 = 1), cg06547715 (OR: 0.92,
259	95% CI: 0.87–0.97; PPH4 = 0.912), and cg14150666 (OR: 0.96, 95% CI: 0.93–0.99; PPH4 =
260	1) shared a causal variant with sepsis, which added another evidence to our results (S14-S16
261	Tables, Fig 5C).

262

Fig 5. SMR and colocalization analysis results in discovery datasets (ieu-b-4980 cohort).
A. MR association between *CXCR2* expression and sepsis risk. B. MR association between *CXCR2* methylation and sepsis risk. C. Colocalization evidence of the expression and CpG
site methylation of *CXCR2* and sepsis susceptibility.

267

Integration of GWAS and CXCR2-related eQTL/mQTL data from the blood

270	Subsequently, we hypothesized that gene expression could be the underlying mechanism
271	explaining the plausible causality in the disease. Moreover, DNA methylation (DNAm) in
272	promoters or enhancers typically plays a crucial role in the regulation of disease-associated
273	target genes. In this study, we identified CXCR2, which encodes a protein belonging to the G
274	protein-coupled receptor family. This protein serves as a receptor for interleukin 8, which
275	binds with high affinity and transmits signals through the G-protein-activated second
276	messenger system. Additionally, this receptor can bind to chemokine (C-X-C motif) ligand 1
277	(CXCL1/MGSA), which is known to stimulate melanoma growth. This receptor mediates the
278	migration of neutrophils to sites of inflammation. After three-step SMR analysis, we
279	discovered that the DNAm probe cg06547715 located in the enhancer region of CXCR2 plays
280	a crucial role in gene expression regulation. Methylation levels at this site negatively correlate
281	with <i>CXCR2</i> expression (β SMR = -0.658) and sepsis (β SMR = -0.082). Conversely, the
282	expression levels of <i>CXCR2</i> are positively correlated with sepsis (β SMR = 0.13). This
283	suggests that reduced DNAm levels within the enhancer region of CXCR2 may upregulate its
284	expression, increasing susceptibility to sepsis (S17 Table).
285	Replication of results in other cohorts

We performed SMR analysis of *CXCR2* in the ieu-b-5088 cohort to validate our findings. The results showed the methylation level at the cg06547715 site negatively correlated with sepsis (β SMR = -0.0604334), and *CXCR2* expression levels were positively correlated with the condition (β SMR = 0.114256), aligning with the effects observed in cohort ieu-b-4980 (**S18 Table**; **Fig 6A**, **B**). Colocalization analysis depicted the details of SNPs locus (**Fig 5B**) and showed that *CXCR2* (OR: 1.12, 95% CI: 1.01–1.24; PPH4=1), cg06547715 (OR: 0.94,

292	95% CI: 0.89–0.99; PPH4=0.912), and cg14150666 (OR 0.97, 95% CI 0.94–1.00; PPH4=1)
293	shared a causal variant with sepsis, which added additional evidence to our results (S19-S21
294	Tables; Fig 6C).
295	
296	Fig 6. SMR and colocalization analysis results in validation datasets (ieu-b-5088 cohort).
297	A. MR association between CXCR2 expression and sepsis risk. B. MR association between
298	CXCR2 methylation and sepsis risk. C. Colocalization evidence of the expression and CpG

site methylation of *CXCR2* and susceptibility to sepsis.

300

301 **Discussion**

302 This study leveraged the multiomic MR method to explore the relationship of NRGs with sepsis risk. Our findings not only contribute to the existing literature but also provide a 303 foundation for future therapeutic interventions. The identification of CXCR1, CXCR2, 304 305 ENTPD4, and MAPK3 as genes significantly associated with sepsis risk is consistent with the growing body of evidence suggesting that chemokine signaling and immune response genes 306 are critical in sepsis pathogenesis. The involvement of CXCR1 underscores the critical role of 307 neutrophil chemotaxis in sepsis. Our findings are consistent with those of previous studies, 308 suggesting that polymorphisms in these genes modulate the immune response to infection[29, 309 30]. The association between ENTPD4 and sepsis risk is intriguing, given its role in 310 311 purinergic signaling, which has been implicated in the regulation of NET formation[31, 32]. Similarly, the observed association with MAPK3, a key regulator of cellular stress responses, 312

aligns with the hypothesis that NETs are part of a broader inflammatory network during 313 sepsis[33, 34]. The robust association of CXCR2, in particular, resonates with prior research 314 indicating its role in modulating neutrophil migration and the inflammatory cascade central to 315 sepsis[35-37]. Our multiomic MR approach, which integrates genetic, epigenetic, and 316 proteomic data, strengthens the causal inference by mitigating confounding and reverse 317 causation biases inherent in observational studies. The results of colocalization analysis 318 provided us with additional evidence supporting the role of the CXCR2 gene in sepsis. Our 319 analysis showed that the gene expression of CXCR2 is significantly associated with the risk of 320 321 sepsis development, and the PPH4 value is greater than 0.75, indicating that the association between GWAS and eQTL may be caused by the same causal variant. This finding further 322 strengthens the possibility of using *CXCR2* as a potential therapeutic target for sepsis. 323

324 The inverse correlation between DNAm at cg06547715 and CXCR2 expression and its subsequent impact on sepsis risk offer a novel perspective on the epigenetic modulation of 325 immune response genes[38, 39]. This aligns with the emerging paradigm that epigenetic 326 327 modifications, especially DNAm, are dynamic and responsive to environmental stimuli, potentially serving as a molecular switch in the context of sepsis[40]. The implications of our 328 findings extend to the realm of therapeutics, where targeting CXCR2 and its regulatory 329 mechanisms could represent a new frontier in sepsis management[30]. The potential to 330 331 modulate gene expression through epigenetic drugs or gene therapies offers a promising avenue for mitigating the hyperinflammatory state characteristic of sepsis. Furthermore, the 332 333 pQTL analysis revealed a direct link between specific proteins and the risk of sepsis development. By screening cis-pQTL data associated with NRGs, we identified 10 proteins 334

that are significantly associated with the risk of sepsis. For instance, SIGLEC14 and SIGLEC5 335 are positively correlated, whereas AKT2, CEACAM3, CTSG, F3, FCAR, HMGB1, IL17A, and 336 ITGB2 are negatively correlated with the risk of sepsis development. These findings suggest 337 that these proteins may play a key role in the pathogenesis of sepsis, offering new leads for 338 the development of targeted therapeutic strategies in the future[41-46]. Our results are in line 339 with those of previous studies that have implicated NRGs in various inflammatory and 340 autoimmune conditions, suggesting a common pathway in the dysregulation of immune 341 responses [47, 48]. The consistency of our findings with those from independent cohorts and 342 343 the replication of results across different analytical approaches lend credence to the robustness of our conclusions. While our multiomic MR approach provides a robust platform 344 for causal inference, it is not without limitations. The reliance on observational data exposes 345 346 our study to potential unmeasured confounding despite the use of MR methods to control for such biases. Due to the limited number of NRG proteins in the pQTL dataset, the present 347 study did not fully explore the causal relationship between mitochondrial proteins and the risk 348 349 of sepsis development.

Future research should aim to replicate our findings in diverse populations and investigate the functional consequences of the genetic and epigenetic variants identified. Additionally, experimental studies are warranted to elucidate the mechanistic links among NRGs, inflammation, and sepsis development, potentially leading to the discovery of new biomarkers and therapeutic targets.

In conclusion, our multiomic MR study provides a deeper understanding of the role of NRGs in sepsis, with a particular focus on *CXCR2*. Our findings have significant implications

357	for the development of precision medicine strategies for sepsis and highlight the importance
358	of integrating genetic and epigenetic data in the quest for novel therapeutic targets. The
359	identification of CXCR2 as a key gene in sepsis risk offers a promising starting point for
360	future research and interventional studies aimed at improving the outcomes in patients with
361	this devastating condition.

362

363 Acknowledgments

We gratefully acknowledge the authors and participants of all GWASs, including the IEU OpenGWAS Project, eQTLgen, the mQTL summary data of McRae et al., and the deCODE Genetics dataset, from which we utilized summary statistics data.

367 **References**

368

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama.
2016;315(8):801-10.

Schlapbach LJ, Watson RS, Sorce LR, Argent AC, Menon K, Hall MW, et al.
 International Consensus Criteria for Pediatric Sepsis and Septic Shock. Jama.
 2024;331(8):665-74.

375 3. De Backer D, Deutschman CS, Hellman J, Myatra SN, Ostermann M, Prescott HC, et al.
 376 Surviving Sepsis Campaign Research Priorities 2023. Critical care medicine.
 377 2024;52(2):268-96.

4. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet (London,
England). 2018;392(10141):75-87.

380 5. Bode C, Weis S, Sauer A, Wendel-Garcia P, David S. Targeting the host response in

sepsis: current approaches and future evidence. Critical care (London, England).
2023;27(1):478.

383 6. Zhang H, Wang Y, Qu M, Li W, Wu D, Cata JP, et al. Neutrophil, neutrophil
384 extracellular traps and endothelial cell dysfunction in sepsis. Clinical and translational
385 medicine. 2023;13(1):e1170.

7. Hamilton FW, Thomas M, Arnold D, Palmer T, Moran E, Mentzer AJ, et al. Therapeutic
potential of IL6R blockade for the treatment of sepsis and sepsis-related death: A Mendelian
randomisation study. PLoS medicine. 2023;20(1):e1004174.

Boufenzer A, Carrasco K, Jolly L, Brustolin B, Di-Pillo E, Derive M, et al. Potentiation
 of NETs release is novel characteristic of TREM-1 activation and the pharmacological
 inhibition of TREM-1 could prevent from the deleterious consequences of NETs release in
 sepsis. Cellular & molecular immunology. 2021;18(2):452-60.

Ou Q, Tan L, Shao Y, Lei F, Huang W, Yang N, et al. Electrostatic Charge-Mediated
 Apoptotic Vesicle Biodistribution Attenuates Sepsis by Switching Neutrophil NETosis to
 Apoptosis. Small (Weinheim an der Bergstrasse, Germany). 2022;18(20):e2200306.

396 10. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a
397 randomised, controlled, open-label, platform trial. Lancet (London, England).
398 2021;397(10285):1637-45.

399 11. Warner S, Teague HL, Ramos-Benitez MJ, Panicker S, Allen K, Gaihre S, et al. R406
400 reduces lipopolysaccharide-induced neutrophil activation. Cellular immunology.
401 2024;403-404:104860.

402 12. Grüneboom A, Aust O, Cibir Z, Weber F, Hermann DM, Gunzer M. Imaging innate
403 immunity. Immunological reviews. 2022;306(1):293-303.

13. Ramoni D, Tirandi A, Montecucco F, Liberale L. Sepsis in elderly patients: the role of
neutrophils in pathophysiology and therapy. Internal and emergency medicine.
2024;19(4):901-17.

407 14. Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nature
408 reviews Immunology. 2018;18(2):134-47.

409 15. Skallberg A, Bunnfors K, Brommesson C, Uvdal K. Neutrophils Activated by
410 Nanoparticles and Formation of Neutrophil Extracellular Traps: Work Function Mapping and
19

- 411 Element Specific Imaging. Analytical chemistry. 2019;91(21):13514-20.
- 412 16. Kolaczkowska E, Jenne CN, Surewaard BG, Thanabalasuriar A, Lee WY, Sanz MJ, et al.
- 413 Molecular mechanisms of NET formation and degradation revealed by intravital imaging in
- the liver vasculature. Nature communications. 2015;6:6673.
- 415 17. Baz AA, Hao H, Lan S, Li Z, Liu S, Chen S, et al. Neutrophil extracellular traps in
 416 bacterial infections and evasion strategies. Frontiers in immunology. 2024;15:1357967.
- 417 18. Kiwit A, Lu Y, Lenz M, Knopf J, Mohr C, Ledermann Y, et al. The Dual Role of
- 418 Neutrophil Extracellular Traps (NETs) in Sepsis and Ischemia-Reperfusion Injury:
- 419 Comparative Analysis across Murine Models. International journal of molecular sciences.
 420 2024;25(7).
- 421 19. Zhu S, Yu Y, Qu M, Qiu Z, Zhang H, Miao C, et al. Neutrophil extracellular traps
- 422 contribute to immunothrombosis formation via the STING pathway in sepsis-associated lung423 injury. Cell death discovery. 2023;9(1):315.
- 424 20. Thiam HR, Wong SL, Wagner DD, Waterman CM. Cellular Mechanisms of NETosis.
 425 Annual review of cell and developmental biology. 2020;36:191-218.
- 426 21. Kumar S, Payal N, Srivastava VK, Kaushik S, Saxena J, Jyoti A. Neutrophil extracellular
- traps and organ dysfunction in sepsis. Clinica chimica acta; international journal of clinical
 chemistry. 2021;523:152-62.
- 429 22. Yao YM, Osuchowski MF, Wang JH, Pan ZK. Editorial: Immune Dysfunction: An
 430 Update of New Immune Cell Subsets and Cytokines in Sepsis. Frontiers in immunology.
 431 2021;12:822068.
- 432 23. Mengozzi L, Barison I, Malý M, Lorenzoni G, Fedrigo M, Castellani C, et al. Neutrophil
 433 Extracellular Traps and Thrombolysis Resistance: New Insights for Targeting Therapies.

434

Stroke. 2024;55(4):963-71.

- 435 24. Zuber V, Colijn JM, Klaver C, Burgess S. Selecting likely causal risk factors from
 436 high-throughput experiments using multivariable Mendelian randomization. Nature
 437 communications. 2020;11(1):29.
- 25. Zhang Y, Guo L, Dai Q, Shang B, Xiao T, Di X, et al. A signature for pan-cancer
 prognosis based on neutrophil extracellular traps. Journal for immunotherapy of cancer.
 2022;10(6).

26. Papadimitriou N, Dimou N, Tsilidis KK, Banbury B, Martin RM, Lewis SJ, et al. 441

- 442 Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation 443 analysis. Nature communications. 2020;11(1):597.
- 27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the 444
- MR-Egger method. European journal of epidemiology. 2017;32(5):377-89. 445
- 28. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. 446
- Bayesian test for colocalisation between pairs of genetic association studies using summary 447
- 448 statistics. PLoS genetics. 2014;10(5):e1004383.
- 29. Zhao H, Li Y, Sun G, Cheng M, Ding X, Wang K. Single-cell transcriptional gene 449
- signature analysis identifies IL-17 signaling pathway as the key pathway in sepsis. 450 451 Immunobiology. 2023;228(6):152763.
- 30. Alsabani M, Abrams ST, Cheng Z, Morton B, Lane S, Alosaimi S, et al. Reduction of 452
- NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in 453 experimental human and murine sepsis. British journal of anaesthesia. 2022;128(2):283-93. 454
- 31. Avital-Shacham M, Sharf R, Kleinberger T. NTPDASE4 gene products cooperate with 455 456 the adenovirus E4orf4 protein through PP2A-dependent and -independent mechanisms and contribute to induction of cell death. Journal of virology. 2014;88(11):6318-28. 457
- 32. Shaikh S, Basu S, Bag S, Chatterjee A, Datta S, Banerjee D, et al. Uracil as a biomarker 458 for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell 459 carcinoma. Scientific reports. 2024;14(1):11609. 460
- 33. Li X, Jiang S, Wang B, He S, Guo X, Lin J, et al. Integrated multi-omics analysis and 461 machine learning developed diagnostic markers and prognostic model based on 462 463 Efferocytosis-associated signatures for septic cardiomyopathy. Clinical immunology 464 (Orlando, Fla). 2024;265:110301.
- 34. Cao B, Xu Z, Liu C, Hu J, Zhu Z, Li J, et al. Protective effects of notoginsenoside R1 on 465 acute lung injury in rats with sepsis. Annals of translational medicine. 2021;9(12):996. 466
- 35. Wu Y, Wang S, Farooq SM, Castelvetere MP, Hou Y, Gao JL, et al. A chemokine 467 468 receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases. The Journal of biological chemistry. 2012;287(8):5744-55. 469
- 36. Boppana NB, Devarajan A, Gopal K, Barathan M, Bakar SA, Shankar EM, et al. 470

471 Blockade of CXCR2 signalling: a potential therapeutic target for preventing
472 neutrophil-mediated inflammatory diseases. Experimental biology and medicine (Maywood,
473 NJ). 2014;239(5):509-18.

474 37. Kim SD, Lee HY, Shim JW, Kim HJ, Yoo YH, Park JS, et al. Activation of CXCR2 by
475 extracellular matrix degradation product acetylated Pro-Gly-Pro has therapeutic effects
476 against sepsis. American journal of respiratory and critical care medicine.
477 2011;184(2):243-51.

- 478 38. Caldwell BA, Wu Y, Wang J, Li L. Altered DNA methylation underlies monocyte
 479 dysregulation and innate exhaustion memory in sepsis. bioRxiv : the preprint server for
 480 biology. 2023.
- 39. Binnie A, Walsh CJ, Hu P, Dwivedi DJ, Fox-Robichaud A, Liaw PC, et al. Epigenetic
 Profiling in Severe Sepsis: A Pilot Study of DNA Methylation Profiles in Critical Illness.
 Critical care medicine. 2020;48(2):142-50.
- 484 40. Martino D, Kresoje N, Amenyogbe N, Ben-Othman R, Cai B, Lo M, et al. DNA
 485 Methylation signatures underpinning blood neutrophil to lymphocyte ratio during first week
 486 of human life. Nature communications. 2024;15(1):8167.
- 487 41. Kim HG, Lee C, Yoon JH, Kim JH, Cho JY. BN82002 alleviated tissue damage of septic
- 488 mice by reducing inflammatory response through inhibiting AKT2/NF-κB signaling pathway.
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022;148:112740.
- 42. Liu YC, Yu MM, Chai YF, Shou ST. Sialic Acids in the Immune Response during491 Sepsis. Frontiers in immunology. 2017;8:1601.
- 43. Klaile E, Müller MM, Schäfer MR, Clauder AK, Feer S, Heyl KA, et al. Binding of
 Candida albicans to Human CEACAM1 and CEACAM6 Modulates the Inflammatory
 Response of Intestinal Epithelial Cells. mBio. 2017;8(2).
- 495 44. You G, Zhao X, Liu J, Yao K, Yi X, Chen H, et al. Machine learning-based
 496 identification of CYBB and FCAR as potential neutrophil extracellular trap-related treatment
 497 targets in sepsis. Frontiers in immunology. 2023;14:1253833.
- 498 45. Deng M, Tang Y, Li W, Wang X, Zhang R, Zhang X, et al. The Endotoxin Delivery
 499 Protein HMGB1 Mediates Caspase-11-Dependent Lethality in Sepsis. Immunity.
 500 2018;49(4):740-53.e7.

- 46. Nakada TA, Russell JA, Boyd JH, Walley KR. IL17A genetic variation is associated
- 502 with altered susceptibility to Gram-positive infection and mortality of severe sepsis. Critical
- 503 care (London, England). 2011;15(5):R254.
- 47. Xiang J, Cao J, Wang X, Shao S, Huang J, Zhang L, et al. Neutrophil extracellular traps
- and neutrophil extracellular traps-related genes are involved in new-onset atrial fibrillation in
- 506 LPS-induced sepsis. International immunopharmacology. 2024;138:112550.
- 48. Tang J, Lu H, Xie Z, Jia X, Su T, Lin B. Identification of potential biomarkers for sepsis
- 508 based on neutrophil extracellular trap-related genes. Diagnostic microbiology and infectious
- 509 disease. 2024;110(1):116380.



Fig 1



	Exposure	MR Method	No.SNP	S	OR(95%CI)	P value	FDR
	CXCR1	Weighted mode	26	h 	1.09(0.97-1.24)	1.66e-01	0.710021365
		MR Egger	26		1.02(0.89-1.16)	8.23e-01	0.956998483
		Simple mode	26	++++++	1.09(0.94-1.27)	2.45e-01	0.804630251
		Weighted median	26		1.09(1.01-1.19)	3.05e-02	0.246785856
		Inverse variance weighted	26	+++	1.11(1.04-1.17)	1.23e-03	0.022144609
	CXCR2	Weighted mode	19		1.14(1.05-1.25)	8.86e-03	0.478346388
		MR Egger	19		1.13(0.98-1.31)	1.12e-01	0.818589551
		Simple mode	19		1.08(0.92-1.27)	3.52e-01	0.804630251
		Weighted median	19		1.15(1.05-1.26)	3.12e-03	0.168643953
		Inverse variance weighted	19	HH4	1.14(1.07-1.21)	9.91e-05	0.002675368
	ENTPD4	Weighted mode	17		1.12(1.03-1.22)	2.18e-02	0.588186781
		MR Egger	17		1.09(0.98-1.22)	1.51e-01	0.818589551
		Simple mode	17		1.12(0.96-1.30)	1.61e-01	0.804630251
		Weighted median	17		1.12(1.03-1.22)	9.91e-03	0.212339894
		Inverse variance weighted	17	H+4	1.16(1.09-1.24)	4.60e-06	0.000248607
	MAPK3	Weighted mode	49		0.98(0.94-1.03)	4.98e-01	0.840670435
preprint (whic	h was not cert	ined by peer review) is the auth	or/funder,	who has granted med Rxiv a license to display	the preprint in .05)	7.18e-01	0.922540104
		Simplifies made available under	erpetuity. a CC-BY 4	.0 International license .	0.92(0.85-0.99)	3.07e-02	0.804630251
		Weighted median	49	Peet	0.98(0.94-1.03)	4.66e-01	0.744742690
		Inverse variance weighted	49	-	0.96(0.93-0.99)	3.40e-03	0.045876179
			~	Protective factor Risk factor			



Exposure	CpG	MR Method	No.SNPs		OR(95%CI)	P value	FDR
CXCR2	cg06547715	Weighted mode	3	Hel	0.92(0.87-0.97)	1.04e-01	8.80e-01
		Weighted median	3	Hel	0.92(0.88-0.97)	1.93e-03	8.60e-02
		Simple mode	3		0.93(0.86-1.01)	2.12e-01	9.51e-01
		MR Egger	3		0.93(0.80-1.07)	4.80e-01	9.99e-01
		Inverse variance weighte	d 3	and .	0.92(0.88-0.97)	6.93e-04	2.06e-02
	cg14150666	Weighted mode	9	141	0.96(0.93-0.99)	2.63e-02	8.80e-01
		Weighted median	9	н	0.95(0.93-0.98)	1.23e-03	8.60e-02
		Simple mode	9	Per l	0.97(0.92-1.02)	2.26e-01	9.51e-01
		MR Egger	9	H-H	0.97(0.91-1.03)	3.97e-01	9.99e-01
		Inverse variance weighte	d 9	H	0.95(0.93-0.97)	3.89e-05	3.46e-03
SLC25A37	cg24126361	Weighted mode	14	H	0.99(0.96-1.01)	2.64e-01	8.80e-01
		Weighted median	14	н	0.97(0.94-0.99)	5.99e-03	1.78e-01
		Simple mode	14	144	0.95(0.91-0.99)	2.62e-02	9.51e-01
		MR Egger	14	÷	0.98(0.95-1.02)	3.44e-01	9.99e-01
		Inverse variance weighte	d 14	H	0.97(0.95-0.99)	5.89e-04	2.06e-02



	Genes	MR Method	No.S	SNPs		OR(95%CI)	P value	FDR
	AKT2	Inverse variance weighted (fixed effects)	57			0.94(0.90-0.97)	7.11e-04	4.41e-03
		MR Egger	57			0.96(0.90-1.02)	1.54e-01	7.39e-01
		Simple mode	57	-		0.94(0.85-1.04)	2.33e-01	5.81e-01
		Weighted median	57		page 1	0.97(0.92-1.03)	3.35e-01	5.23e-01
		Weighted mode	57			0.97(0.92-1.02)	2.17e-01	5.08e-01
	CEACAM3	Inverse variance weighted (fixed effects)	13		1	0.75(0.66-0.85)	7.33e-06	7.57e-05
		MR Egger	13			0.88(0.57-1.36)	5.72e-01	7.39e-01
		Simple mode	13		-	0.74(0.56-0.99)	6.58e-02	5.81e-01
		Weighted median	13		-	0.79(0.67-0.95)	1.06e-02	1.17e-01
		Weighted mode	13		-	0.82(0.67-1.01)	8.98e-02	3.40e-01
	CTSG	Inverse variance weighted (fixed effects)	13			0.80(0.69-0.92)	1.98e-03	8.77e-03
		MR Egger	13	·		0.86(0.56-1.32)	5.01e-01	7.39e-01
		Simple mode	13			0.78(0.56-1.07)	1.49e-01	5.81e-01
		Weighted median	13		4	0.80(0.66-0.98)	3.22e-02	1.47e-01
		Weighted mode	13		+	0.80(0.63-1.02)	9.86e-02	3.40e-01
	F3	Inverse variance weighted (fixed effects)	12			0.71(0.61-0.82)	4.63e-06	7.57e-05
		MR Egger	12			0.88(0.47-1.67)	7.03e-01	8.38e-01
		Simple mode	12			0.80(0.57-1.11)	2.04e-01	5.81e-01
		Weighted median	12			0.76(0.61-0.94)	1.13e-02	1.17e-01
		Weighted mode	12		-	0.83(0.58-1.17)	3.09e-01	5.54e-01
medRxiv preprin	t doi: https://doi	org/10.1101/2024.12.24.24319599; this ver	rsion p	costed December 27, 2	2024. The copyright ho	Ider for this	6.00e-03	2.07e-02
preprint (whic	ir was not cert	MR Egger perpetuity.	who-h 3		license to display the	0.87(0.28-2.72)	8.50e-01	9.11e-01
		It is made available under a CC-BY 4	.0 Inte	ernational license .	+	0.75(0.50-1.13)	3.03e-01	6.27e-01
		Weighted median	3		-	0.75(0.58-0.99)	3.91e-02	1.47e-01
		Weighted mode	3		-	0.77(0.56-1.06)	2.46e-01	5.08e-01
	HMGB1	Inverse variance weighted (fixed effects)	25	H-1		0.83(0.76-0.90)	7.26e-06	7.57e-05
		MR Egger	25			0.89(0.71-1.13)	3.54e-01	7.39e-01
		Simple mode	25			0.77(0.63-0.95)	2.49e-02	5.81e-01
		Weighted median	25	++	4	0.87(0.77-0.98)	1.94e-02	1.47e-01
		Weighted mode	25	→	4	0.87(0.76-0.99)	4.67e-02	3.40e-01
	IL17A	Inverse variance weighted (fixed effects)	3			0.63(0.44-0.90)	1.14e-02	3.55e-02
		MR Egger	3	-		0.02(0.00-10.91)	4.32e-01	7.39e-01
		Simple mode	3			0.69(0.43-1.11)	2.62e-01	5.81e-01
		Weighted median	3		4	0.68(0.46-1.01)	5.43e-02	1.53e-01
		Weighted mode	3			0.68(0.44-1.07)	2.35e-01	5.08e-01
	ITGB2	Inverse variance weighted (fixed effects)	16	++-1	1	0.77(0.69-0.88)	4.11e-05	3.19e-04
		MR Egger	16			0.79(0.54-1.14)	2.29e-01	7.39e-01
		Simple mode	16		4	0.77(0.58-1.03)	1.00e-01	5.81e-01
		Weighted median	16			0.80(0.67-0.94)	7.01e-03	1.17e-01
		Weighted mode	16		-	0.82(0.67-1.01)	7.76e-02	3.40e-01
	SIGLEC14	Inverse variance weighted (fixed effects)	313	3		1.02(1.01-1.04)	1.56e-03	8.05e-03
		MR Egger	313	3		1.03(1.01-1.06)	1.13e-02	1.87e-01
		Simple mode	313	1		1.06(1.00-1.11)	4.39e-02	5.81e-01
		Weighted median	313	8	-	1.03(1.00-1.05)	3.40e-02	1.47e-01
		Weighted mode	313	3	-	1.03(1.00-1.06)	3.99e-02	3.40e-01
	SIGLEC5	Inverse variance weighted (fixed effects)	294		4	1.02(1.01-1.04)	2.92e-03	1.13e-02
		MR Egger	294		1	1.03(1.01-1.06)	1.21e-02	1.87e-01
		Simple mode	294			1.04(0.99-1.10)	9.64e-02	5.81e-01
		Weighted median	294		-	1.03(1.00-1.05)	4.28e-02	1.47e-01
		Weighted mode	294	1	in the second se	1.03(1.00-1.06)	3.31e-02	3.40e-01
				Į.	1	1		
				0	·	2		
				Protective factor	Risk	factor		













